Efficacy of nirogacestat in participants with poor prognostic factors for desmoid tumors: Analyses from the randomized phase 3 DeFi study.

Bruno Vincenzi,Nam Bui,Palma Dileo,Noah Federman,Richard F. Riedel,Brian Andrew Van Tine,Vincent Amoruccio,Allison Lim,Ana B. Oton,Bernd Kasper

DOI: https://doi.org/10.1200/jco.2024.42.16_suppl.11556

IF: 45.3

2024-06-01

Journal of Clinical Oncology

Abstract:11556 Background: Desmoid tumors (DT) are rare, locally aggressive, soft-tissue tumors with a highly unpredictable natural course and substantial patient burden, including pain and functional limitations. Prognosis of DT is potentially dependent on multiple factors, including tumor location, size, patient’s age, mutational status, and presence of pain. Nirogacestat (niro), a targeted gamma secretase inhibitor, is the only treatment approved in the US for adults with progressing DT. In the phase 3 DeFi study, niro demonstrated significant and clinically meaningful improvement vs placebo (pbo) in the primary and key secondary endpoints of progression-free survival (PFS: HR, 0.29 [95% CI: 0.15-0.55]; P30 y); CTNNB1 mutation type (S45F, T41A); and baseline pain (uncontrolled, controlled) (Table). Across the subgroups analyzed, PFS hazard ratio ranged from 0.18 to 0.39, with values 0 favoring niro. Conclusions: Niro demonstrated consistent improvement in PFS and ORR vs pbo in patients with characteristics implicated as poor prognostic factors for DT—including larger tumor size, younger age, CTNNB1 mutation types, and pain. These results indicate that niro can provide substantial benefit across the subgroups analyzed. Clinical trial information: NCT03785964 . [Table: see text]

oncology